What are the major Antiplatelet Drug Classes (Aspirin, P2Y12 Inhibitors, GP IIb/IIIa Inhibitors, PDE3 Inhibitors), their mechanisms of action, and preoperative holding windows?

1) Aspirin (ASA): irreversibly acetylates platelet COX-1 (for the 7–10 day lifespan of the platelet), blocking Thromboxane A2 (TXA2) synthesis; 2) P2Y12 ADP-Receptor Blockers: Clopidogrel, Prasugrel (irreversible thienopyridines; hold Clopidogrel 5 days and Prasugrel 7 days before elective surgery/CABG; note Clopidogrel is a prodrug activated by CYP2C19 — avoid Omeprazole), and Ticagrelor (reversible; hold 3–5 days; IV Cangrelor is ultra-short-acting); 3) Glycoprotein IIb/IIIa Inhibitors (Abciximab, Eptifibatide, Tirofiban): block final common pathway of fibrinogen cross-linking platelets during PCI; 4) Cilostazol / Dipyridamole: inhibit platelet phosphodiesterase-3 (PDE3), increasing cAMP for platelet inhibition and vasodilation in peripheral artery disease claudication (contraindicated in heart failure).

How do you recognize and treat Tricyclic Antidepressant (TCA: Amitriptyline, Nortriptyline) Overdose ('The 3 Cs'), and why is IV Sodium Bicarbonate the life-saving antidote?

TCAs exert anticholinergic, alpha-1 blocking, H1 antihistamine, GABA-A blocking, and fast cardiac Na+-channel blocking (Class IA-like) effects, producing the '3 Cs': Convulsions (seizures), Coma (and hyperthermia/anticholinergic toxidrome), and Cardiotoxicity (hypotension and widened QRS complex > 100 ms progressing to ventricular tachycardia/fibrillation, plus prominent R wave in aVR > 3 mm). Whenever QRS duration is > 100 ms (0.10 s) or ventricular arrhythmia/hypotension occurs, immediately administer IV Sodium Bicarbonate boluses (1–2 mEq/kg IV push, targeting serum pH 7.45–7.55): the high extracellular Na+ load overcomes competitive fast Na+-channel blockade while alkalemia reduces TCA binding to myocardial sodium channels.

How do you clinically distinguish Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and Malignant Hyperthermia, and what are their specific pharmacological treatments?

1) Serotonin Syndrome (SSRIs/SNRIs + MAOIs, linezolid, tramadol, triptans, MDMA, or St. John's Wort; rapid onset within treat by stopping serotonergic agents, benzodiazepines, cooling, and the 5-HT2A antagonist Cyproheptadine; 2) Neuroleptic Malignant Syndrome (D2 dopamine antagonists [haloperidol, fluphenazine] or abrupt withdrawal of levodopa; evolves over 1–3 days): 'FEVER' — Fever, Encephalopathy, Vitals unstable, Elevated Creatine Kinase (rhabdomyolysis), and 'LEAD-PIPE' MUSCLE RIGIDITY with hyporeflexia/bradykinesia -> treat by stopping neuroleptic, cooling/IV fluids, and Dantrolene (ryanodine receptor antagonist) or Bromocriptine (D2 agonist); 3) Malignant Hyperthermia (autosomal dominant RYR1 mutation triggered minutes after inhaled volatile anesthetics [sevoflurane, halothane] or succinylcholine): rapid rise in End-Tidal CO2 (earliest sign in OR!), masseter spasm, generalized rigidity, extreme hyperthermia, hyperkalemia, and rhabdomyolysis -> immediate cessation of anesthetic, 100% O2 hyperventilation, and IV Dantrolene.

What is the mechanism of action of Warfarin (Coumadin), why does it cause a transient Hypercoagulable State during the first 3–5 days of initiation, and when is Heparin Bridging required?

Warfarin inhibits Vitamin K Epoxide Reductase (VKORC1), blocking hepatic gamma-carboxylation of Vitamin K-dependent clotting factors II, VII, IX, and X as well as endogenous anticoagulants Protein C and Protein S; because anticoagulant Protein C (and Factor VII) has a short half-life (~6–8 hours) while prothrombotic Factor II (prothrombin) has a long half-life (~60 hours), initial Warfarin depletion of Protein C creates a transient hypercoagulable state that can cause Warfarin-Induced Skin Necrosis (especially in hereditary Protein C/S deficiency) -> bridge high-risk VTE/mechanical valve patients with Unfractionated Heparin or Enoxaparin for >= 5 days AND until the INR is therapeutic (>= 2.0) for at least 24 hours.

What are the clinical stages and acid-base evolution of Acute Salicylate (Aspirin) Overdose, and how does IV Sodium Bicarbonate ('Ion Trapping') work as its treatment?

Presents with tinnitus (earliest sign — CN VIII toxicity), hyperthermia (uncouples mitochondrial oxidative phosphorylation), tachypnea, diaphoresis, nausea/vomiting, and altered mental status; early direct stimulation of the medullary respiratory center causes a Primary Respiratory Alkalosis, followed shortly by uncoupled aerobic metabolism and organic acid accumulation causing a concurrent High Anion Gap Metabolic Acidosis (classic mixed acid-base disorder). Treatment: Activated charcoal + IV Sodium Bicarbonate infusion to alkalinize the serum (pH 7.45–7.55, preventing salicylic acid from crossing into the CNS) and alkalinize the URINE to pH 7.5–8.0 (converting non-ionized salicylic acid [HA] into ionized salicylate [A-] that cannot be reabsorbed by renal tubules — 'ion trapping' — while replete K+ is maintained), plus Hemodialysis for levels > 90–100 mg/dL, pulmonary edema, renal failure, or coma/seizures.

What is the standard Dual Antiplatelet Therapy (DAPT) regimen after Acute Coronary Syndrome or Coronary Stent Placement, and why is premature discontinuation catastrophic?

Low-dose Aspirin (81 mg daily indefinitely) PLUS a P2Y12 inhibitor (Ticagrelor, Prasugrel, or Clopidogrel) for at least 12 months after an ACS or Drug-Eluting Stent (DES) placement (minimum 1 month for Bare-Metal Stent or 3–6 months in high bleeding risk); premature cessation of DAPT before endothelialization of stent struts precipitates acute In-Stent Thrombosis, which carries a 20–45% mortality rate.

What is the maximum safe 24-hour adult dose of Acetaminophen (Paracetamol), what toxic metabolite causes centrilobular hepatic necrosis, and how are the Rumack-Matthew Nomogram and N-Acetylcysteine (NAC) used?

Maximum adult dose is 4,000 mg/day (4 g/day; or 7.5–10 g or > 150 mg/kg), sulfation/glucuronidation pathways saturate and CYP2E1 converts acetaminophen into the hepatotoxic metabolite NAPQI, which depletes hepatic Glutathione and destroys Zone 3 centrilobular hepatocytes; plot a serum acetaminophen level drawn at >= 4 hours post-ingestion on the Rumack-Matthew Nomogram (plus activated charcoal if 24 hours if fulminant hepatic failure is present).

What are the therapeutic target trough concentrations (or AUC/MIC targets) for IV Vancomycin, when should a Vancomycin Trough be drawn, and what are its major toxicities?

Vancomycin trough must be drawn at steady state (30 minutes BEFORE the 4th dose): traditional target trough is 10–15 mcg/mL for uncomplicated skin/UTI infections and 15–20 mcg/mL for severe invasive MRSA infections (bacteremia, endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia), though modern ASHP/IDSA guidelines favor 24-hour AUC/MIC ratio of 400–600 mg·h/L to reduce nephrotoxicity; major toxicities are Nephrotoxicity (acute tubular necrosis, synergistic when combined with piperacillin-tazobactam or aminoglycosides), Ototoxicity, and Vancomycin Flushing Syndrome ('Red Man Syndrome' — non-IgE direct mast cell histamine release over face/neck/upper torso from rapid infusion -> prevent by infusing over >= 60–120 minutes and pre-medicating with antihistamines).

What are the major Blood Transfusion Reactions (Acute Hemolytic, Febrile Non-Hemolytic, Allergic/Anaphylactic, TRALI, TACO), and what is the immediate nursing action for ANY suspected transfusion reaction?

Immediate First Step for ANY suspected reaction: STOP the blood transfusion immediately, keep the IV line open with fresh 0.9% Normal Saline using new IV tubing (do NOT flush the blood remaining in the old tubing into the patient), verify patient/blood bag ID tags, notify the provider and blood bank, and send the blood bag/tubing plus patient blood/urine samples for Coombs test and hemolysis workup. Specific types: 1) Acute Hemolytic (ABO incompatibility — Type II hypersensitivity within minutes): fever, chills, flank/back pain, hemoglobinuria, hypotension, DIC; 2) Febrile Non-Hemolytic (most common, recipient antibodies against donor WBC cytokines): temp rise >= 1°C within 1–6 hrs without hemolysis (prevented by leukoreduction); 3) Anaphylactic (within minutes in selective IgA-deficient patient receiving IgA-containing blood): bronchospasm, angioedema, shock -> IM Epinephrine; 4) TRALI (Transfusion-Related Acute Lung Injury — donor anti-HLA/anti-neutrophil antibodies activate neutrophils in pulmonary capillaries within 6 hrs): non-cardiogenic pulmonary edema (bilateral infiltrates, PaO2/FiO2 treat with upright positioning and IV Furosemide).

What are the therapeutic serum reference ranges for the antiepileptic drugs Phenytoin (Total and Free), Valproic Acid, Carbamazepine, and Phenobarbital?

Total Phenytoin: 10–20 mcg/mL (Free/Unbound Phenytoin: 1.0–2.0 mcg/mL); Valproic Acid (Valproate): 50–100 mcg/mL (up to 125 mcg/mL in mania); Carbamazepine: 4–12 mcg/mL; Phenobarbital: 15–40 mcg/mL.

What is Heparin-Induced Thrombocytopenia (HIT Type II), what is its pathophysiology and timing ('4Ts Score'), and how must it be treated?

Pathophysiology: IgG autoantibodies form against complexes of Heparin bound to Platelet Factor 4 (PF4); the Fc portion of IgG binds platelet FcγIIa receptors, activating platelets, releasing microparticles, and causing CONSUMPTIVE THROMBOCYTOPENIA plus paradoxical life-threatening arterial and venous THROMBOSIS ('white clot syndrome'). Timing ('4Ts'): 1) Thrombocytopenia (> 50% drop in platelet count from baseline, nadir typically 20,000–100,000/mm³), 2) Timing of 5 to 10 days after starting UFH or LMWH (or < 24 hours if heparin exposure within prior 100 days), 3) Thrombosis (DVT/PE, limb ischemia, skin necrosis), 4) No other cause. Immediate Management: 1) STOP all heparin products (including heparin flushes and LMWH) and NEVER give warfarin alone or platelet transfusions initially; 2) Start a non-heparin Direct Thrombin Inhibitor (IV Argatroban [hepatic clearance — safe in renal failure] or Bivalirudin [renal/proteolytic]) or Fondaparinux; 3) Confirm with PF4 ELISA + Serotonin Release Assay (SRA).

What are the clinical signs of Local Anesthetic Systemic Toxicity (LAST

Early CNS excitation: circumoral numbness/tingling, metallic taste in the mouth, tinnitus, visual changes, muscle twitching, and generalized tonic-clonic seizures (followed by CNS depression/coma and respiratory arrest); Cardiovascular collapse (especially with cardiotoxic Bupivacaine): severe bradycardia, AV block, hypotension, wide-complex ventricular arrhythmias, and refractory asystole -> immediate rescue antidote (alongside airway management and benzodiazepines for seizures) is 20% Intravenous Lipid Emulsion ('Lipid Rescue'

When administering Subcutaneous Enoxaparin (Lovenox) or Unfractionated Heparin, what injection site and technique reduce hematoma formation?

Inject into the anterolateral or posterolateral abdominal wall fat pad ('love handles') at least 2 inches (5 cm) away from the umbilicus, scars, or bruises; pinch a skinfold and insert the needle at a 90-degree angle (45 degrees in very thin patients), DO NOT expel the prefilled air bubble in Enoxaparin syringes (air lock seals the drug in tissue), DO NOT aspirate before injecting, and DO NOT rub or massage the site afterward.

What metabolic and hemostatic complications occur during Massive Blood Transfusion Protocol (MTP — >= 10 units pRBCs in 24 hours or >= 4 units in 1 hour)?

The 'Lethal Triad' of trauma/massive transfusion is Hypothermia (warm all blood products), Acidosis, and Coagulopathy (dilutional thrombocytopenia and clotting factor depletion -> prevented by balanced 1:1:1 resuscitation of Packed RBCs : Fresh Frozen Plasma : Platelets plus Tranexamic Acid [TXA] within 3 hours of injury), PLUS Citrate Toxicity: sodium citrate anticoagulant in banked blood chelates serum ionized Calcium and Magnesium, causing severe HYPOCALCEMIA (prolonged QT, hypotension, coagulopathy -> replete with IV Calcium Chloride/Gluconate) and metabolic alkalosis (as liver converts citrate to bicarbonate), as well as HYPERKALEMIA (potassium leaks out of older stored/irradiated RBCs).

What are the long-term renal, endocrine, and teratogenic adverse effects of chronic Lithium therapy?

1) Nephrogenic Diabetes Insipidus (Lithium enters principal cells via ENaC channels and inhibits GSK-3beta/cAMP-mediated Aquaporin-2 insertion -> polyuria and polydipsia; treated with Amiloride, which blocks ENaC lithium entry); 2) Hypothyroidism (and hyperparathyroidism/hypercalcemia); 3) Ebstein Anomaly in pregnancy (apical displacement of the tricuspid valve leaflets causing 'atrialization' of the right ventricle and severe tricuspid regurgitation).

What are the narrow therapeutic serum reference ranges and toxic thresholds for Lithium, Digoxin, and Theophylline?

Lithium: 0.6–1.2 mEq/L (acute mania 0.8–1.2 mEq/L, maintenance 0.6–1.0 mEq/L; toxic > 1.5 mEq/L; severe/dialyzable > 2.5 mEq/L); Digoxin: 0.5–2.0 ng/mL (specifically 0.5–0.9 ng/mL in Heart Failure, 0.8–2.0 ng/mL in AFib; toxic > 2.0 ng/mL); Theophylline: 10–20 mcg/mL (often targeted at 5–15 mcg/mL; toxic > 20 mcg/mL).

What is the evidence-based management protocol for a Supratherapeutic INR on Warfarin (INR 4.5–10 without bleeding, INR > 10 without bleeding, and Any INR with Serious/Life-Threatening Bleeding)?

1) INR 4.5–10.0 WITHOUT bleeding: HOLD 1–2 doses of Warfarin and monitor INR (routine Vitamin K is not needed unless high bleeding risk); 2) INR > 10.0 WITHOUT bleeding: HOLD Warfarin and administer Oral Vitamin K1 (Phytonadione) 2.5–5 mg PO (lowers INR within 24 hours); 3) Any elevated INR WITH serious or life-threatening bleeding (e.g., intracranial hemorrhage or massive GI bleed): HOLD Warfarin, administer 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra — immediately replaces Factors II, VII, IX, X within 15 minutes; or Fresh Frozen Plasma [FFP] if PCC is unavailable) PLUS slow IV Vitamin K1 10 mg (needed for sustained hepatic synthesis once PCC wears off).

What are the major black-box organ toxicities and teratogenic risks of Valproic Acid (Valproate) and Carbamazepine?

Valproic Acid: fatal hepatotoxicity (especially children check serum ammonia and treat with L-carnitine), acute hemorrhagic pancreatitis, thrombocytopenia, alopecia/weight gain, and Neural Tube Defects (spina bifida/myelomeningocele via folate antagonism); Carbamazepine: SIADH (euvolemic hyponatremia), agranulocytosis / aplastic anemia (requires baseline and periodic CBC monitoring), hepatic CYP450 auto-induction, Stevens-Johnson syndrome / TEN (screen for HLA-B*1502 allele in patients of Asian ancestry prior to starting), and neural tube defects.

Why does Phenytoin exhibit Zero-Order (Michaelis-Menten saturation) kinetics at high therapeutic concentrations, and how do you adjust Total Phenytoin for Hypoalbuminemia or Renal Failure (Winter-Tozer equation)?

Hepatic CYP2C9/2C19 hydroxylation enzymes saturate near the therapeutic range, so small dose increases cause disproportionately large, exponential jumps in serum concentration and toxicity; because Phenytoin is ~90% bound to albumin, hypoalbuminemia or uremia (which displaces phenytoin from albumin) lowers Total Phenytoin while Free (active) Phenytoin is normal or toxic -> Winter-Tozer Equation: Corrected Phenytoin = Measured Total Phenytoin / [(0.2 × Albumin) + 0.1] (use 0.1 instead of 0.2 if CrCl < 10 mL/min, or directly measure a Free Phenytoin level).

What is the mechanism of action of Digoxin, why does Hypokalemia precipitate Digoxin Toxicity even at normal digoxin levels, and what are the classic symptoms and antidote?

Digoxin inhibits the sarcolemmal Na+/K+-ATPase pump (raising intracellular Na+, which reduces NCX Ca2+ extrusion and increases SR Ca2+ stores for positive inotropy) and increases vagal tone at the AV node; Potassium and Digoxin compete for the SAME binding site on the Na+/K+-ATPase pump, so Hypokalemia (from loop/thiazide diuretics) dramatically increases digoxin binding and toxicity (along with renal insufficiency, verapamil, amiodarone, and quinidine); presents with anorexia, nausea/vomiting, confusion, visual disturbances (yellow-green halos / xanthopsia), hyperkalemia (in acute overdose), and arrhythmias -> antidote is Digoxin Immune Fab (Digibind).

What are the clinical manifestations and treatment of Theophylline Toxicity (serum level > 20 mcg/mL), and which CYP1A2 inhibitors precipitate it?

Theophylline (methylxanthine bronchodilator that inhibits phosphodiesterase and antagonizes adenosine receptors) is metabolized by hepatic CYP1A2; levels rise to toxic ranges when co-administered with CYP1A2 inhibitors (Ciprofloxacin, Erythromycin/Clarithromycin, Cimetidine, Fluvoxamine) or in heart failure/cirrhosis (smoking induces CYP1A2 and lowers levels); toxicity presents with severe nausea/vomiting, tremor, restlessness, hypokalemia, hyperglycemia, supraventricular/ventricular arrhythmias (MAT, VT), and refractory status epilepticus -> treat with multi-dose activated charcoal, beta-blockers (esmolol), benzodiazepines, and Hemodialysis.

What are the classic acute concentration-dependent neurological signs versus chronic idiosyncratic/teratogenic adverse effects of Phenytoin?

Acute concentration-dependent cerebellar/vestibular toxicity (> 20 mcg/mL): horizontal nystagmus (earliest sign at > 20), diplopia, cerebellar gait ataxia (> 30), slurred speech (dysarthria), and lethargy/coma (> 40); Chronic adverse effects: gingival hyperplasia (prevented with oral hygiene/folate), hirsutism, coarsened facial features, megaloblastic anemia (folate malabsorption), osteopenia (vitamin D catabolism), peripheral neuropathy, Stevens-Johnson syndrome/DRESS, and Fetal Hydantoin Syndrome (cleft lip/palate, nail/digital hypoplasia, cardiac defects).

Which other high-risk medications require routine laboratory monitoring for organ or hematologic toxicity (Clozapine, Methotrexate, Amiodarone, Statins, ACEi/ARBs/Spironolactone, Linezolid)?

Clozapine: baseline and periodic ANC monitoring for severe Agranulocytosis (hold if ANC < 1,000/mm³ in general population; note FDA removed the centralized Clozapine REMS in 2025 while preserving prescribing-label ANC monitoring) + myocarditis/metabolic syndrome; Methotrexate: CBC, LFTs, and Creatinine (causes hepatotoxicity, bone marrow suppression/pancytopenia [rescued with Leucovorin/folinic acid], and pulmonary fibrosis); Amiodarone: baseline and q6m TFTs (hypo- or hyperthyroidism), LFTs, CXR/PFTs (pulmonary fibrosis), and slit-lamp exam (corneal microdeposits/optic neuropathy); Statins: baseline lipid panel and LFTs, plus Creatine Kinase (CK) if myopathy/rhabdomyolysis symptoms occur; ACEi/ARBs/Spironolactone: Serum K+ and Creatinine within 1–2 weeks of initiation (acceptable Cr rise up to 30%); Linezolid: weekly CBC for thrombocytopenia (> 14 days use) and serotonin syndrome with SSRIs.

Match the heavy metal poisonings (Lead, Iron, Arsenic/Mercury, Copper, Cyanide) to their clinical hallmarks and specific chelating agents / antidotes.

1) Lead (old paint/pipes/batteries -> 'LEAD': Lead lines on gingiva [Burton lines] and metaphyses on X-ray, Encephalopathy/cognitive decline, Abdominal colic & constipation, Drops [wrist/foot drop] + microcytic anemia with basophilic stippling due to inhibited ALA dehydratase and ferrochelatase): Succimer (DMSA, oral for children with level > 45 mcg/dL), or Dimercaprol (BAL) + Calcium Disodium EDTA (for severe lead encephalopathy > 70 mcg/dL); 2) Iron (pediatric prenatal vitamin overdose -> hemorrhagic gastroenteritis, high anion gap metabolic acidosis, hepatic necrosis, late GI scarring): Deferoxamine (IV; turns urine 'vin rosé' pink) or oral Deferasirox/Deferiprone; 3) Arsenic (garlic breath, watery 'rice-water' diarrhea, QTc prolongation, palmoplantar keratosis) & Mercury: Dimercaprol (BAL) or Succimer; 4) Copper (Wilson disease — ATP7B mutation, Kayser-Fleischer corneal rings, cirrhosis, basal ganglia parkinsonism): Penicillamine or Trientine + Zinc; 5) Cyanide (house fire smoke inhalation or nitroprusside infusion -> bitter almond odor, bright red venous blood, severe lactic acidosis): Hydroxocobalamin (Vitamin B12a, binds cyanide to form non-toxic cyanocobalamin excreted in urine; or Nitrites + Sodium Thiosulfate).

How do Dietary Vitamin K intake and CYP2C9 Drug Interactions ('On-On-On' inhibitors vs. Inducers) alter a Warfarin patient's INR?

Patients on Warfarin should NOT avoid green leafy vegetables (spinach, kale, broccoli, Brussels sprouts), but must maintain a CONSISTENT daily Vitamin K intake (sudden increase in greens lowers INR; sudden decrease raises INR). Drugs that INHIBIT CYP2C9 or gut flora Vitamin K synthesis INCREASE the INR and bleeding risk: Metronidazole, TMP-SMX (Bactrim), Fluconazole, Amiodarone, Ciprofloxacin, Macrolides, Cimetidine, Omeprazole, and Acute Alcohol binges. Drugs that INDUCE CYP2C9 DECREASE the INR and cause thrombosis: Rifampin, Carbamazepine, Phenytoin, Phenobarbital, St. John's Wort, and Chronic Alcoholism.

Why must IV Phenytoin be infused slowly (<= 50 mg/min) in Normal Saline (never Dextrose), and why is Fosphenytoin safer?

Parenteral Phenytoin is poorly water-soluble (precipitates into crystals if mixed with D5W) and is formulated in a propylene glycol / ethanol vehicle at pH 12; rapid IV infusion (> 50 mg/min) causes severe hypotension and cardiac arrhythmias (from both sodium channel blockade and the propylene glycol diluent), and extravasation causes 'Purple Glove Syndrome' (limb-threatening tissue necrosis); Fosphenytoin is a water-soluble phosphate prodrug lacking propylene glycol that can be infused 3 times faster (up to 150 mg PE/min IV or IM).

What are the Direct Oral Anticoagulants (DOACs), how do you distinguish Factor Xa Inhibitors from Direct Thrombin Inhibitors by their generic name stems, and what are their specific reversal agents?

Direct Factor Xa Inhibitors ('-xaban' stem: Apixaban, Rivaroxaban, Edoxaban): directly bind and inhibit free and clot-bound Factor Xa; specific FDA-approved reversal agent for life-threatening bleeding is Andexanet alfa (coagulation factor Xa recombinant, inactivated-zhzo) or 4-Factor PCC. Direct Oral Thrombin (Factor IIa) Inhibitor: Dabigatran etexilate; specific reversal agent is Idarucizumab (Praxbind, humanized monoclonal antibody fragment that binds dabigatran with 350× greater affinity than thrombin) or hemodialysis.

When should a Serum Lithium level be drawn relative to the dose, what drugs/states precipitate Lithium Toxicity, and how do Mild, Moderate, and Severe Lithium Toxicity present?

Draw a 12-hour trough level in the morning immediately before the next dose; because Lithium is handled by the proximal renal tubule identically to Sodium (Na+), volume depletion (dehydration, vomiting/diarrhea, low-sodium diet), Thiazide diuretics, NSAIDs (except aspirin), and ACE inhibitors/ARBs increase proximal Li+ reabsorption and precipitate toxicity; Mild toxicity (1.5–2.0 mEq/L): coarse hand tremor (vs. benign fine tremor at therapeutic levels), nausea, diarrhea, polyuria; Moderate (2.0–2.5 mEq/L): ataxia, slurred speech, confusion, myoclonus, fasciculations; Severe (> 2.5 mEq/L): seizures, coma, renal failure -> treat with aggressive IV 0.9% Normal Saline and emergent Hemodialysis.

Compare the mechanism of action, route, monitoring test, renal clearance, and reversal of Unfractionated Heparin (UFH) versus Low-Molecular-Weight Heparin (Enoxaparin) and Fondaparinux.

Unfractionated Heparin (IV or SubQ, short half-life 60–90 min, hepatic/reticuloendothelial clearance — preferred in severe renal failure CrCl monitored via aPTT (1.5–2.5× baseline, or anti-Xa 0.3–0.7 IU/mL) and 100% reversed by IV Protamine Sulfate (1 mg per 100 units of UFH); Enoxaparin (LMWH, SubQ, renal clearance — contraindicated/dose-adjusted if CrCl IIa -> routine monitoring not needed (except anti-Xa levels in pregnancy, morbid obesity, or CKD) and only ~60% partially reversed by Protamine; Fondaparinux (synthetic pentasaccharide): pure selective Factor Xa inhibitor via Antithrombin III (no HIT cross-reactivity).

What is Tumor Lysis Syndrome (TLS), what laboratory tetrad defines it (Cairo-Bishop criteria), and how is it prevented and treated?

Rapid lysis of malignant cells (after initiating chemotherapy for high-grade lymphomas [Burkitt] or acute leukemias with high WBC count) spills intracellular contents into the bloodstream, producing the electrolyte tetrad of: 1) Hyperuricemia (nucleic acid purine breakdown > 8 mg/dL, precipitating uric acid crystals in renal tubules and causing acute kidney injury), 2) Hyperkalemia (> 6.0 mEq/L -> fatal arrhythmias), 3) Hyperphosphatemia (> 4.5 mg/dL), and 4) Secondary Hypocalcemia ( tetany/seizures). Prevention: aggressive IV Isotonic Hydration + Allopurinol (xanthine oxidase inhibitor, prevents NEW uric acid formation) in intermediate risk; Treatment of established TLS or high-risk prophylaxis: Rasburicase (recombinant urate oxidase enzyme that directly converts existing insoluble uric acid into water-soluble allantoin — CONTRAINDICATED in G6PD deficiency because it generates H2O2 and causes severe hemolysis!).

Match the following emergency toxicology syndromes to their specific first-line antidotes: Opioid overdose, Benzodiazepine overdose, Organophosphate/Carbamate poisoning, Anticholinergic toxicity, Beta-blocker overdose, and Calcium Channel Blocker overdose.

1) Opioids (fentanyl, morphine, heroin — respiratory depression, pinpoint miosis, coma): Naloxone (Narcan, competitive mu-opioid antagonist; short half-life 30–90 min -> watch for renarcotization); 2) Benzodiazepines (midazolam, diazepam): Flumazenil (competitive GABA-A benzodiazepine site antagonist — CAUTION: precipitates refractory seizures in chronic benzodiazepine dependence or co-ingestion of TCAs); 3) Organophosphates / Nerve agents ('DUMBELS' cholinergic crisis: Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia/Bronchorrhea, Emesis, Lacrimation, Salivation): Atropine (blocks muscarinic receptors; titrate to dry bronchial secretions) FOLLOWED by Pralidoxime (2-PAM, regenerates acetylcholinesterase at nicotinic NMJ before 'aging' occurs); 4) Anticholinergic toxicity ('blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone'): Physostigmine (tertiary amine cholinesterase inhibitor that crosses the BBB); 5) Beta-Blocker overdose (bradycardia, hypotension, hypoglycemia): IV Glucagon (activates myocardial Gs adenylyl cyclase -> cAMP bypassing the beta-1 receptor) + high-dose insulin euglycemia; 6) Calcium Channel Blocker overdose (bradycardia, hypotension, HYPERGLYCEMIA from blocked pancreatic beta-cell L-type Ca2+ channels): IV Calcium Chloride/Gluconate + High-Dose Insulin (1–10 U/kg/hr) with Dextrose ('HDI therapy').

What are the target Peak and Trough levels for conventional dosing of Aminoglycosides (Gentamicin/Tobramycin vs. Amikacin), when are they drawn, and what correlates with Peak vs. Trough levels?

Draw Trough 30 minutes BEFORE the next dose and Peak 30 minutes AFTER completion of a 30-minute IV infusion: Gentamicin/Tobramycin target Peak is 5–10 mcg/mL and Trough is < 1–2 mcg/mL; Amikacin target Peak is 20–35 mcg/mL and Trough is < 5–10 mcg/mL. Because aminoglycosides exhibit concentration-dependent bactericidal killing and a prolonged post-antibiotic effect, the PEAK level correlates with bacterial killing efficacy, whereas persistently elevated TROUGH levels correlate with Nephrotoxicity (proximal tubular necrosis, reversible) and Ototoxicity (irreversible cochlear hair cell deafness and vestibular vertigo/ataxia) + neuromuscular blockade.

Therapeutic Drug Monitoring (TDM: Lithium, Digoxin, Vancomycin, Phenytoin, Valproate, Aminoglycosides, Theophylline) & Anticoagulation Protocols

Narrow therapeutic index reference ranges, peak vs trough timing, toxicity signs, specific antidotes, warfarin/heparin/LMWH/DOAC reversal & HIT

Level: advanced
Languages: en → en
Cards: 32
Markdown: Therapeutic Drug Monitoring (TDM: Lithium, Digoxin, Vancomycin, Phenytoin, Valproate, Aminoglycosides, Theophylline) & Anticoagulation Protocols (.md)

Flashcards (32)

#	Front (Term / Question)	Back (Definition / Answer)	Example
1	What are the major Antiplatelet Drug Classes (Aspirin, P2Y12 Inhibitors, GP IIb/IIIa Inhibitors, PDE3 Inhibitors), their mechanisms of action, and preoperative holding windows?	1) Aspirin (ASA): irreversibly acetylates platelet COX-1 (for the 7–10 day lifespan of the platelet), blocking Thromboxane A2 (TXA2) synthesis; 2) P2Y12 ADP-Receptor Blockers: Clopidogrel, Prasugrel (irreversible thienopyridines; hold Clopidogrel 5 days and Prasugrel 7 days before elective surgery/CABG; note Clopidogrel is a prodrug activated by CYP2C19 — avoid Omeprazole), and Ticagrelor (reversible; hold 3–5 days; IV Cangrelor is ultra-short-acting); 3) Glycoprotein IIb/IIIa Inhibitors (Abciximab, Eptifibatide, Tirofiban): block final common pathway of fibrinogen cross-linking platelets during PCI; 4) Cilostazol / Dipyridamole: inhibit platelet phosphodiesterase-3 (PDE3), increasing cAMP for platelet inhibition and vasodilation in peripheral artery disease claudication (contraindicated in heart failure).
2	How do you recognize and treat Tricyclic Antidepressant (TCA: Amitriptyline, Nortriptyline) Overdose ('The 3 Cs'), and why is IV Sodium Bicarbonate the life-saving antidote?	TCAs exert anticholinergic, alpha-1 blocking, H1 antihistamine, GABA-A blocking, and fast cardiac Na+-channel blocking (Class IA-like) effects, producing the '3 Cs': Convulsions (seizures), Coma (and hyperthermia/anticholinergic toxidrome), and Cardiotoxicity (hypotension and widened QRS complex > 100 ms progressing to ventricular tachycardia/fibrillation, plus prominent R wave in aVR > 3 mm). Whenever QRS duration is > 100 ms (0.10 s) or ventricular arrhythmia/hypotension occurs, immediately administer IV Sodium Bicarbonate boluses (1–2 mEq/kg IV push, targeting serum pH 7.45–7.55): the high extracellular Na+ load overcomes competitive fast Na+-channel blockade while alkalemia reduces TCA binding to myocardial sodium channels.
3	How do you clinically distinguish Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and Malignant Hyperthermia, and what are their specific pharmacological treatments?	1) Serotonin Syndrome (SSRIs/SNRIs + MAOIs, linezolid, tramadol, triptans, MDMA, or St. John's Wort; rapid onset within < 24 hours): triad of autonomic instability (hyperthermia, tachycardia, diaphoresis, diarrhea), altered mental status (agitation), and NEUROMUSCULAR HYPERACTIVITY — specifically HYPERREFLEXIA and inducible/ocular CLONUS (worse in lower extremities) -> treat by stopping serotonergic agents, benzodiazepines, cooling, and the 5-HT2A antagonist Cyproheptadine; 2) Neuroleptic Malignant Syndrome (D2 dopamine antagonists [haloperidol, fluphenazine] or abrupt withdrawal of levodopa; evolves over 1–3 days): 'FEVER' — Fever, Encephalopathy, Vitals unstable, Elevated Creatine Kinase (rhabdomyolysis), and 'LEAD-PIPE' MUSCLE RIGIDITY with hyporeflexia/bradykinesia -> treat by stopping neuroleptic, cooling/IV fluids, and Dantrolene (ryanodine receptor antagonist) or Bromocriptine (D2 agonist); 3) Malignant Hyperthermia (autosomal dominant RYR1 mutation triggered minutes after inhaled volatile anesthetics [sevoflurane, halothane] or succinylcholine): rapid rise in End-Tidal CO2 (earliest sign in OR!), masseter spasm, generalized rigidity, extreme hyperthermia, hyperkalemia, and rhabdomyolysis -> immediate cessation of anesthetic, 100% O2 hyperventilation, and IV Dantrolene.
4	What is the mechanism of action of Warfarin (Coumadin), why does it cause a transient Hypercoagulable State during the first 3–5 days of initiation, and when is Heparin Bridging required?	Warfarin inhibits Vitamin K Epoxide Reductase (VKORC1), blocking hepatic gamma-carboxylation of Vitamin K-dependent clotting factors II, VII, IX, and X as well as endogenous anticoagulants Protein C and Protein S; because anticoagulant Protein C (and Factor VII) has a short half-life (~6–8 hours) while prothrombotic Factor II (prothrombin) has a long half-life (~60 hours), initial Warfarin depletion of Protein C creates a transient hypercoagulable state that can cause Warfarin-Induced Skin Necrosis (especially in hereditary Protein C/S deficiency) -> bridge high-risk VTE/mechanical valve patients with Unfractionated Heparin or Enoxaparin for >= 5 days AND until the INR is therapeutic (>= 2.0) for at least 24 hours.
5	What are the clinical stages and acid-base evolution of Acute Salicylate (Aspirin) Overdose, and how does IV Sodium Bicarbonate ('Ion Trapping') work as its treatment?	Presents with tinnitus (earliest sign — CN VIII toxicity), hyperthermia (uncouples mitochondrial oxidative phosphorylation), tachypnea, diaphoresis, nausea/vomiting, and altered mental status; early direct stimulation of the medullary respiratory center causes a Primary Respiratory Alkalosis, followed shortly by uncoupled aerobic metabolism and organic acid accumulation causing a concurrent High Anion Gap Metabolic Acidosis (classic mixed acid-base disorder). Treatment: Activated charcoal + IV Sodium Bicarbonate infusion to alkalinize the serum (pH 7.45–7.55, preventing salicylic acid from crossing into the CNS) and alkalinize the URINE to pH 7.5–8.0 (converting non-ionized salicylic acid [HA] into ionized salicylate [A-] that cannot be reabsorbed by renal tubules — 'ion trapping' — while replete K+ is maintained), plus Hemodialysis for levels > 90–100 mg/dL, pulmonary edema, renal failure, or coma/seizures.
6	What is the standard Dual Antiplatelet Therapy (DAPT) regimen after Acute Coronary Syndrome or Coronary Stent Placement, and why is premature discontinuation catastrophic?	Low-dose Aspirin (81 mg daily indefinitely) PLUS a P2Y12 inhibitor (Ticagrelor, Prasugrel, or Clopidogrel) for at least 12 months after an ACS or Drug-Eluting Stent (DES) placement (minimum 1 month for Bare-Metal Stent or 3–6 months in high bleeding risk); premature cessation of DAPT before endothelialization of stent struts precipitates acute In-Stent Thrombosis, which carries a 20–45% mortality rate.
7	What is the maximum safe 24-hour adult dose of Acetaminophen (Paracetamol), what toxic metabolite causes centrilobular hepatic necrosis, and how are the Rumack-Matthew Nomogram and N-Acetylcysteine (NAC) used?	Maximum adult dose is 4,000 mg/day (4 g/day; or <= 2,000 mg/day in chronic liver disease/alcoholism); in overdose (> 7.5–10 g or > 150 mg/kg), sulfation/glucuronidation pathways saturate and CYP2E1 converts acetaminophen into the hepatotoxic metabolite NAPQI, which depletes hepatic Glutathione and destroys Zone 3 centrilobular hepatocytes; plot a serum acetaminophen level drawn at >= 4 hours post-ingestion on the Rumack-Matthew Nomogram (plus activated charcoal if < 4 hours), and administer the antidote N-Acetylcysteine (NAC — replenishes cysteine/glutathione sulfhydryl stores; most effective within 8 hours, but still given even > 24 hours if fulminant hepatic failure is present).
8	What are the therapeutic target trough concentrations (or AUC/MIC targets) for IV Vancomycin, when should a Vancomycin Trough be drawn, and what are its major toxicities?	Vancomycin trough must be drawn at steady state (30 minutes BEFORE the 4th dose): traditional target trough is 10–15 mcg/mL for uncomplicated skin/UTI infections and 15–20 mcg/mL for severe invasive MRSA infections (bacteremia, endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia), though modern ASHP/IDSA guidelines favor 24-hour AUC/MIC ratio of 400–600 mg·h/L to reduce nephrotoxicity; major toxicities are Nephrotoxicity (acute tubular necrosis, synergistic when combined with piperacillin-tazobactam or aminoglycosides), Ototoxicity, and Vancomycin Flushing Syndrome ('Red Man Syndrome' — non-IgE direct mast cell histamine release over face/neck/upper torso from rapid infusion -> prevent by infusing over >= 60–120 minutes and pre-medicating with antihistamines).
9	What are the major Blood Transfusion Reactions (Acute Hemolytic, Febrile Non-Hemolytic, Allergic/Anaphylactic, TRALI, TACO), and what is the immediate nursing action for ANY suspected transfusion reaction?	Immediate First Step for ANY suspected reaction: STOP the blood transfusion immediately, keep the IV line open with fresh 0.9% Normal Saline using new IV tubing (do NOT flush the blood remaining in the old tubing into the patient), verify patient/blood bag ID tags, notify the provider and blood bank, and send the blood bag/tubing plus patient blood/urine samples for Coombs test and hemolysis workup. Specific types: 1) Acute Hemolytic (ABO incompatibility — Type II hypersensitivity within minutes): fever, chills, flank/back pain, hemoglobinuria, hypotension, DIC; 2) Febrile Non-Hemolytic (most common, recipient antibodies against donor WBC cytokines): temp rise >= 1°C within 1–6 hrs without hemolysis (prevented by leukoreduction); 3) Anaphylactic (within minutes in selective IgA-deficient patient receiving IgA-containing blood): bronchospasm, angioedema, shock -> IM Epinephrine; 4) TRALI (Transfusion-Related Acute Lung Injury — donor anti-HLA/anti-neutrophil antibodies activate neutrophils in pulmonary capillaries within 6 hrs): non-cardiogenic pulmonary edema (bilateral infiltrates, PaO2/FiO2 < 300, normal JVD/BNP/PAWP, hypotension); 5) TACO (Transfusion-Associated Circulatory Overload): cardiogenic pulmonary edema from rapid volume overload (hypertension, JVD, S3 gallop, elevated BNP/PAWP -> treat with upright positioning and IV Furosemide).
10	What are the therapeutic serum reference ranges for the antiepileptic drugs Phenytoin (Total and Free), Valproic Acid, Carbamazepine, and Phenobarbital?	Total Phenytoin: 10–20 mcg/mL (Free/Unbound Phenytoin: 1.0–2.0 mcg/mL); Valproic Acid (Valproate): 50–100 mcg/mL (up to 125 mcg/mL in mania); Carbamazepine: 4–12 mcg/mL; Phenobarbital: 15–40 mcg/mL.
11	What is Heparin-Induced Thrombocytopenia (HIT Type II), what is its pathophysiology and timing ('4Ts Score'), and how must it be treated?	Pathophysiology: IgG autoantibodies form against complexes of Heparin bound to Platelet Factor 4 (PF4); the Fc portion of IgG binds platelet FcγIIa receptors, activating platelets, releasing microparticles, and causing CONSUMPTIVE THROMBOCYTOPENIA plus paradoxical life-threatening arterial and venous THROMBOSIS ('white clot syndrome'). Timing ('4Ts'): 1) Thrombocytopenia (> 50% drop in platelet count from baseline, nadir typically 20,000–100,000/mm³), 2) Timing of 5 to 10 days after starting UFH or LMWH (or < 24 hours if heparin exposure within prior 100 days), 3) Thrombosis (DVT/PE, limb ischemia, skin necrosis), 4) No other cause. Immediate Management: 1) STOP all heparin products (including heparin flushes and LMWH) and NEVER give warfarin alone or platelet transfusions initially; 2) Start a non-heparin Direct Thrombin Inhibitor (IV Argatroban [hepatic clearance — safe in renal failure] or Bivalirudin [renal/proteolytic]) or Fondaparinux; 3) Confirm with PF4 ELISA + Serotonin Release Assay (SRA).
12	What are the clinical signs of Local Anesthetic Systemic Toxicity (LAST	Early CNS excitation: circumoral numbness/tingling, metallic taste in the mouth, tinnitus, visual changes, muscle twitching, and generalized tonic-clonic seizures (followed by CNS depression/coma and respiratory arrest); Cardiovascular collapse (especially with cardiotoxic Bupivacaine): severe bradycardia, AV block, hypotension, wide-complex ventricular arrhythmias, and refractory asystole -> immediate rescue antidote (alongside airway management and benzodiazepines for seizures) is 20% Intravenous Lipid Emulsion ('Lipid Rescue'	e.g., accidental intravascular injection of Bupivacaine or Lidocaine), and what is the life-saving rescue antidote? — 1.5 mL/kg bolus followed by infusion, which creates an intravascular 'lipid sink' and shuttles fatty-acid energy to myocardium; avoid vasopressin, beta-blockers, CCBs, and additional lidocaine).
13	When administering Subcutaneous Enoxaparin (Lovenox) or Unfractionated Heparin, what injection site and technique reduce hematoma formation?	Inject into the anterolateral or posterolateral abdominal wall fat pad ('love handles') at least 2 inches (5 cm) away from the umbilicus, scars, or bruises; pinch a skinfold and insert the needle at a 90-degree angle (45 degrees in very thin patients), DO NOT expel the prefilled air bubble in Enoxaparin syringes (air lock seals the drug in tissue), DO NOT aspirate before injecting, and DO NOT rub or massage the site afterward.
14	What metabolic and hemostatic complications occur during Massive Blood Transfusion Protocol (MTP — >= 10 units pRBCs in 24 hours or >= 4 units in 1 hour)?	The 'Lethal Triad' of trauma/massive transfusion is Hypothermia (warm all blood products), Acidosis, and Coagulopathy (dilutional thrombocytopenia and clotting factor depletion -> prevented by balanced 1:1:1 resuscitation of Packed RBCs : Fresh Frozen Plasma : Platelets plus Tranexamic Acid [TXA] within 3 hours of injury), PLUS Citrate Toxicity: sodium citrate anticoagulant in banked blood chelates serum ionized Calcium and Magnesium, causing severe HYPOCALCEMIA (prolonged QT, hypotension, coagulopathy -> replete with IV Calcium Chloride/Gluconate) and metabolic alkalosis (as liver converts citrate to bicarbonate), as well as HYPERKALEMIA (potassium leaks out of older stored/irradiated RBCs).
15	What are the long-term renal, endocrine, and teratogenic adverse effects of chronic Lithium therapy?	1) Nephrogenic Diabetes Insipidus (Lithium enters principal cells via ENaC channels and inhibits GSK-3beta/cAMP-mediated Aquaporin-2 insertion -> polyuria and polydipsia; treated with Amiloride, which blocks ENaC lithium entry); 2) Hypothyroidism (and hyperparathyroidism/hypercalcemia); 3) Ebstein Anomaly in pregnancy (apical displacement of the tricuspid valve leaflets causing 'atrialization' of the right ventricle and severe tricuspid regurgitation).
16	What are the narrow therapeutic serum reference ranges and toxic thresholds for Lithium, Digoxin, and Theophylline?	Lithium: 0.6–1.2 mEq/L (acute mania 0.8–1.2 mEq/L, maintenance 0.6–1.0 mEq/L; toxic > 1.5 mEq/L; severe/dialyzable > 2.5 mEq/L); Digoxin: 0.5–2.0 ng/mL (specifically 0.5–0.9 ng/mL in Heart Failure, 0.8–2.0 ng/mL in AFib; toxic > 2.0 ng/mL); Theophylline: 10–20 mcg/mL (often targeted at 5–15 mcg/mL; toxic > 20 mcg/mL).
17	What is the evidence-based management protocol for a Supratherapeutic INR on Warfarin (INR 4.5–10 without bleeding, INR > 10 without bleeding, and Any INR with Serious/Life-Threatening Bleeding)?	1) INR 4.5–10.0 WITHOUT bleeding: HOLD 1–2 doses of Warfarin and monitor INR (routine Vitamin K is not needed unless high bleeding risk); 2) INR > 10.0 WITHOUT bleeding: HOLD Warfarin and administer Oral Vitamin K1 (Phytonadione) 2.5–5 mg PO (lowers INR within 24 hours); 3) Any elevated INR WITH serious or life-threatening bleeding (e.g., intracranial hemorrhage or massive GI bleed): HOLD Warfarin, administer 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra — immediately replaces Factors II, VII, IX, X within 15 minutes; or Fresh Frozen Plasma [FFP] if PCC is unavailable) PLUS slow IV Vitamin K1 10 mg (needed for sustained hepatic synthesis once PCC wears off).
18	What are the major black-box organ toxicities and teratogenic risks of Valproic Acid (Valproate) and Carbamazepine?	Valproic Acid: fatal hepatotoxicity (especially children < 2 yrs), hyperammonemic encephalopathy (even with normal LFTs -> check serum ammonia and treat with L-carnitine), acute hemorrhagic pancreatitis, thrombocytopenia, alopecia/weight gain, and Neural Tube Defects (spina bifida/myelomeningocele via folate antagonism); Carbamazepine: SIADH (euvolemic hyponatremia), agranulocytosis / aplastic anemia (requires baseline and periodic CBC monitoring), hepatic CYP450 auto-induction, Stevens-Johnson syndrome / TEN (screen for HLA-B*1502 allele in patients of Asian ancestry prior to starting), and neural tube defects.
19	Why does Phenytoin exhibit Zero-Order (Michaelis-Menten saturation) kinetics at high therapeutic concentrations, and how do you adjust Total Phenytoin for Hypoalbuminemia or Renal Failure (Winter-Tozer equation)?	Hepatic CYP2C9/2C19 hydroxylation enzymes saturate near the therapeutic range, so small dose increases cause disproportionately large, exponential jumps in serum concentration and toxicity; because Phenytoin is ~90% bound to albumin, hypoalbuminemia or uremia (which displaces phenytoin from albumin) lowers Total Phenytoin while Free (active) Phenytoin is normal or toxic -> Winter-Tozer Equation: Corrected Phenytoin = Measured Total Phenytoin / [(0.2 × Albumin) + 0.1] (use 0.1 instead of 0.2 if CrCl < 10 mL/min, or directly measure a Free Phenytoin level).
20	What is the mechanism of action of Digoxin, why does Hypokalemia precipitate Digoxin Toxicity even at normal digoxin levels, and what are the classic symptoms and antidote?	Digoxin inhibits the sarcolemmal Na+/K+-ATPase pump (raising intracellular Na+, which reduces NCX Ca2+ extrusion and increases SR Ca2+ stores for positive inotropy) and increases vagal tone at the AV node; Potassium and Digoxin compete for the SAME binding site on the Na+/K+-ATPase pump, so Hypokalemia (from loop/thiazide diuretics) dramatically increases digoxin binding and toxicity (along with renal insufficiency, verapamil, amiodarone, and quinidine); presents with anorexia, nausea/vomiting, confusion, visual disturbances (yellow-green halos / xanthopsia), hyperkalemia (in acute overdose), and arrhythmias -> antidote is Digoxin Immune Fab (Digibind).
21	What are the clinical manifestations and treatment of Theophylline Toxicity (serum level > 20 mcg/mL), and which CYP1A2 inhibitors precipitate it?	Theophylline (methylxanthine bronchodilator that inhibits phosphodiesterase and antagonizes adenosine receptors) is metabolized by hepatic CYP1A2; levels rise to toxic ranges when co-administered with CYP1A2 inhibitors (Ciprofloxacin, Erythromycin/Clarithromycin, Cimetidine, Fluvoxamine) or in heart failure/cirrhosis (smoking induces CYP1A2 and lowers levels); toxicity presents with severe nausea/vomiting, tremor, restlessness, hypokalemia, hyperglycemia, supraventricular/ventricular arrhythmias (MAT, VT), and refractory status epilepticus -> treat with multi-dose activated charcoal, beta-blockers (esmolol), benzodiazepines, and Hemodialysis.
22	What are the classic acute concentration-dependent neurological signs versus chronic idiosyncratic/teratogenic adverse effects of Phenytoin?	Acute concentration-dependent cerebellar/vestibular toxicity (> 20 mcg/mL): horizontal nystagmus (earliest sign at > 20), diplopia, cerebellar gait ataxia (> 30), slurred speech (dysarthria), and lethargy/coma (> 40); Chronic adverse effects: gingival hyperplasia (prevented with oral hygiene/folate), hirsutism, coarsened facial features, megaloblastic anemia (folate malabsorption), osteopenia (vitamin D catabolism), peripheral neuropathy, Stevens-Johnson syndrome/DRESS, and Fetal Hydantoin Syndrome (cleft lip/palate, nail/digital hypoplasia, cardiac defects).
23	Which other high-risk medications require routine laboratory monitoring for organ or hematologic toxicity (Clozapine, Methotrexate, Amiodarone, Statins, ACEi/ARBs/Spironolactone, Linezolid)?	Clozapine: baseline and periodic ANC monitoring for severe Agranulocytosis (hold if ANC < 1,000/mm³ in general population; note FDA removed the centralized Clozapine REMS in 2025 while preserving prescribing-label ANC monitoring) + myocarditis/metabolic syndrome; Methotrexate: CBC, LFTs, and Creatinine (causes hepatotoxicity, bone marrow suppression/pancytopenia [rescued with Leucovorin/folinic acid], and pulmonary fibrosis); Amiodarone: baseline and q6m TFTs (hypo- or hyperthyroidism), LFTs, CXR/PFTs (pulmonary fibrosis), and slit-lamp exam (corneal microdeposits/optic neuropathy); Statins: baseline lipid panel and LFTs, plus Creatine Kinase (CK) if myopathy/rhabdomyolysis symptoms occur; ACEi/ARBs/Spironolactone: Serum K+ and Creatinine within 1–2 weeks of initiation (acceptable Cr rise up to 30%); Linezolid: weekly CBC for thrombocytopenia (> 14 days use) and serotonin syndrome with SSRIs.
24	Match the heavy metal poisonings (Lead, Iron, Arsenic/Mercury, Copper, Cyanide) to their clinical hallmarks and specific chelating agents / antidotes.	1) Lead (old paint/pipes/batteries -> 'LEAD': Lead lines on gingiva [Burton lines] and metaphyses on X-ray, Encephalopathy/cognitive decline, Abdominal colic & constipation, Drops [wrist/foot drop] + microcytic anemia with basophilic stippling due to inhibited ALA dehydratase and ferrochelatase): Succimer (DMSA, oral for children with level > 45 mcg/dL), or Dimercaprol (BAL) + Calcium Disodium EDTA (for severe lead encephalopathy > 70 mcg/dL); 2) Iron (pediatric prenatal vitamin overdose -> hemorrhagic gastroenteritis, high anion gap metabolic acidosis, hepatic necrosis, late GI scarring): Deferoxamine (IV; turns urine 'vin rosé' pink) or oral Deferasirox/Deferiprone; 3) Arsenic (garlic breath, watery 'rice-water' diarrhea, QTc prolongation, palmoplantar keratosis) & Mercury: Dimercaprol (BAL) or Succimer; 4) Copper (Wilson disease — ATP7B mutation, Kayser-Fleischer corneal rings, cirrhosis, basal ganglia parkinsonism): Penicillamine or Trientine + Zinc; 5) Cyanide (house fire smoke inhalation or nitroprusside infusion -> bitter almond odor, bright red venous blood, severe lactic acidosis): Hydroxocobalamin (Vitamin B12a, binds cyanide to form non-toxic cyanocobalamin excreted in urine; or Nitrites + Sodium Thiosulfate).
25	How do Dietary Vitamin K intake and CYP2C9 Drug Interactions ('On-On-On' inhibitors vs. Inducers) alter a Warfarin patient's INR?	Patients on Warfarin should NOT avoid green leafy vegetables (spinach, kale, broccoli, Brussels sprouts), but must maintain a CONSISTENT daily Vitamin K intake (sudden increase in greens lowers INR; sudden decrease raises INR). Drugs that INHIBIT CYP2C9 or gut flora Vitamin K synthesis INCREASE the INR and bleeding risk: Metronidazole, TMP-SMX (Bactrim), Fluconazole, Amiodarone, Ciprofloxacin, Macrolides, Cimetidine, Omeprazole, and Acute Alcohol binges. Drugs that INDUCE CYP2C9 DECREASE the INR and cause thrombosis: Rifampin, Carbamazepine, Phenytoin, Phenobarbital, St. John's Wort, and Chronic Alcoholism.
26	Why must IV Phenytoin be infused slowly (<= 50 mg/min) in Normal Saline (never Dextrose), and why is Fosphenytoin safer?	Parenteral Phenytoin is poorly water-soluble (precipitates into crystals if mixed with D5W) and is formulated in a propylene glycol / ethanol vehicle at pH 12; rapid IV infusion (> 50 mg/min) causes severe hypotension and cardiac arrhythmias (from both sodium channel blockade and the propylene glycol diluent), and extravasation causes 'Purple Glove Syndrome' (limb-threatening tissue necrosis); Fosphenytoin is a water-soluble phosphate prodrug lacking propylene glycol that can be infused 3 times faster (up to 150 mg PE/min IV or IM).
27	What are the Direct Oral Anticoagulants (DOACs), how do you distinguish Factor Xa Inhibitors from Direct Thrombin Inhibitors by their generic name stems, and what are their specific reversal agents?	Direct Factor Xa Inhibitors ('-xaban' stem: Apixaban, Rivaroxaban, Edoxaban): directly bind and inhibit free and clot-bound Factor Xa; specific FDA-approved reversal agent for life-threatening bleeding is Andexanet alfa (coagulation factor Xa recombinant, inactivated-zhzo) or 4-Factor PCC. Direct Oral Thrombin (Factor IIa) Inhibitor: Dabigatran etexilate; specific reversal agent is Idarucizumab (Praxbind, humanized monoclonal antibody fragment that binds dabigatran with 350× greater affinity than thrombin) or hemodialysis.
28	When should a Serum Lithium level be drawn relative to the dose, what drugs/states precipitate Lithium Toxicity, and how do Mild, Moderate, and Severe Lithium Toxicity present?	Draw a 12-hour trough level in the morning immediately before the next dose; because Lithium is handled by the proximal renal tubule identically to Sodium (Na+), volume depletion (dehydration, vomiting/diarrhea, low-sodium diet), Thiazide diuretics, NSAIDs (except aspirin), and ACE inhibitors/ARBs increase proximal Li+ reabsorption and precipitate toxicity; Mild toxicity (1.5–2.0 mEq/L): coarse hand tremor (vs. benign fine tremor at therapeutic levels), nausea, diarrhea, polyuria; Moderate (2.0–2.5 mEq/L): ataxia, slurred speech, confusion, myoclonus, fasciculations; Severe (> 2.5 mEq/L): seizures, coma, renal failure -> treat with aggressive IV 0.9% Normal Saline and emergent Hemodialysis.
29	Compare the mechanism of action, route, monitoring test, renal clearance, and reversal of Unfractionated Heparin (UFH) versus Low-Molecular-Weight Heparin (Enoxaparin) and Fondaparinux.	Unfractionated Heparin (IV or SubQ, short half-life 60–90 min, hepatic/reticuloendothelial clearance — preferred in severe renal failure CrCl < 30 mL/min): binds Antithrombin III to inactivate BOTH Factor IIa (thrombin) and Factor Xa equally -> monitored via aPTT (1.5–2.5× baseline, or anti-Xa 0.3–0.7 IU/mL) and 100% reversed by IV Protamine Sulfate (1 mg per 100 units of UFH); Enoxaparin (LMWH, SubQ, renal clearance — contraindicated/dose-adjusted if CrCl < 30 mL/min): binds Antithrombin III to preferentially inhibit Factor Xa > IIa -> routine monitoring not needed (except anti-Xa levels in pregnancy, morbid obesity, or CKD) and only ~60% partially reversed by Protamine; Fondaparinux (synthetic pentasaccharide): pure selective Factor Xa inhibitor via Antithrombin III (no HIT cross-reactivity).
30	What is Tumor Lysis Syndrome (TLS), what laboratory tetrad defines it (Cairo-Bishop criteria), and how is it prevented and treated?	Rapid lysis of malignant cells (after initiating chemotherapy for high-grade lymphomas [Burkitt] or acute leukemias with high WBC count) spills intracellular contents into the bloodstream, producing the electrolyte tetrad of: 1) Hyperuricemia (nucleic acid purine breakdown > 8 mg/dL, precipitating uric acid crystals in renal tubules and causing acute kidney injury), 2) Hyperkalemia (> 6.0 mEq/L -> fatal arrhythmias), 3) Hyperphosphatemia (> 4.5 mg/dL), and 4) Secondary Hypocalcemia (< 7.0 mg/dL, caused by calcium-phosphate precipitation -> tetany/seizures). Prevention: aggressive IV Isotonic Hydration + Allopurinol (xanthine oxidase inhibitor, prevents NEW uric acid formation) in intermediate risk; Treatment of established TLS or high-risk prophylaxis: Rasburicase (recombinant urate oxidase enzyme that directly converts existing insoluble uric acid into water-soluble allantoin — CONTRAINDICATED in G6PD deficiency because it generates H2O2 and causes severe hemolysis!).
31	Match the following emergency toxicology syndromes to their specific first-line antidotes: Opioid overdose, Benzodiazepine overdose, Organophosphate/Carbamate poisoning, Anticholinergic toxicity, Beta-blocker overdose, and Calcium Channel Blocker overdose.	1) Opioids (fentanyl, morphine, heroin — respiratory depression, pinpoint miosis, coma): Naloxone (Narcan, competitive mu-opioid antagonist; short half-life 30–90 min -> watch for renarcotization); 2) Benzodiazepines (midazolam, diazepam): Flumazenil (competitive GABA-A benzodiazepine site antagonist — CAUTION: precipitates refractory seizures in chronic benzodiazepine dependence or co-ingestion of TCAs); 3) Organophosphates / Nerve agents ('DUMBELS' cholinergic crisis: Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia/Bronchorrhea, Emesis, Lacrimation, Salivation): Atropine (blocks muscarinic receptors; titrate to dry bronchial secretions) FOLLOWED by Pralidoxime (2-PAM, regenerates acetylcholinesterase at nicotinic NMJ before 'aging' occurs); 4) Anticholinergic toxicity ('blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone'): Physostigmine (tertiary amine cholinesterase inhibitor that crosses the BBB); 5) Beta-Blocker overdose (bradycardia, hypotension, hypoglycemia): IV Glucagon (activates myocardial Gs adenylyl cyclase -> cAMP bypassing the beta-1 receptor) + high-dose insulin euglycemia; 6) Calcium Channel Blocker overdose (bradycardia, hypotension, HYPERGLYCEMIA from blocked pancreatic beta-cell L-type Ca2+ channels): IV Calcium Chloride/Gluconate + High-Dose Insulin (1–10 U/kg/hr) with Dextrose ('HDI therapy').
32	What are the target Peak and Trough levels for conventional dosing of Aminoglycosides (Gentamicin/Tobramycin vs. Amikacin), when are they drawn, and what correlates with Peak vs. Trough levels?	Draw Trough 30 minutes BEFORE the next dose and Peak 30 minutes AFTER completion of a 30-minute IV infusion: Gentamicin/Tobramycin target Peak is 5–10 mcg/mL and Trough is < 1–2 mcg/mL; Amikacin target Peak is 20–35 mcg/mL and Trough is < 5–10 mcg/mL. Because aminoglycosides exhibit concentration-dependent bactericidal killing and a prolonged post-antibiotic effect, the PEAK level correlates with bacterial killing efficacy, whereas persistently elevated TROUGH levels correlate with Nephrotoxicity (proximal tubular necrosis, reversible) and Ototoxicity (irreversible cochlear hair cell deafness and vestibular vertigo/ataxia) + neuromuscular blockade.